INSERT INTO kol_info VALUES 
	('Sang-Cheol Bae', 'lupus_erythematosus', 'Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea (Republic of).', 116.2, 13, 27, 10.0), 
	('Vibeke Strand', 'lupus_erythematosus', 'Division of Immunology/Rheumatology, 6429Stanford University School of Medicine, Palo Alto, California, USA.', 129.4, 5, 30, 12.0), 
	('Zahir Amoura', 'lupus_erythematosus', 'Groupe Hospitalier Pitié-Salpêtrière, Institut E3M, and Université Pierre et Marie Curie, Paris, France.', 195.6, 5, 31, 11.0), 
	('Fengchun Zhang', 'lupus_erythematosus', 'Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.', 210.4, 5, 28, 9.0), 
	('Ricard Cervera', 'lupus_erythematosus', 'Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Catalonia, Spain. Electronic address: rcervera@clinic.cat.', 224.2, 4, 20, 12.0), 
	('David Isenberg', 'lupus_erythematosus', 'University College London, London, UK.', 235.6, 5, 25, 10.0), 
	('Roger A Levy', 'lupus_erythematosus', 'Rio de Janeiro State University, Pedro Ernesto University Hospital, Rio de Janeiro, Brazil.', 257.6, 3, 21, 12.0), 
	('Michelle Petri', 'lupus_erythematosus', 'Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA mpetri@jhmi.edu.', 260.4, 8, 43, 8.0), 
	('Rui-Xue Leng', 'lupus_erythematosus', NULL, 262.8, 8, 33, 10.0), 
	('Jing Li', 'lupus_erythematosus', NULL, 271.0, 4, 22, 9.0), 
	('Xiang-Pei Li', 'lupus_erythematosus', '3 Department of Rheumatology, Anhui Provincial Hospital, Hefei, Anhui, China.', 271.2, 4, 17, 10.0), 
	('David D'Cruz', 'lupus_erythematosus', NULL, 274.8, 5, 21, 9.0), 
	('Yong-Fei Wang', 'lupus_erythematosus', 'University of Hong Kong, Hong Kong, China, and Shenzhen Futian Hospital for Rheumatic Diseases, Shenzhen, China.', 286.0, 5, 28, 10.0), 
	('Doruk Erkan', 'lupus_erythematosus', 'Weill Cornell Medicine, New York, New York.', 302.6, 6, 30, 11.0), 
	('Mengtao Li', 'lupus_erythematosus', 'Department of Rheumatology, Peking Union Medical College Hospital, 1 Shuaifuyuan, Dongcheng District, Beijing, 100730, China.', 316.6, 5, 25, 9.0), 
	('Bin Wang', 'lupus_erythematosus', 'Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China.', 324.0, 7, 33, 7.0), 
	('Xiao-Mei Li', 'lupus_erythematosus', 'Department of Rheumatology and Immunology, Anhui Provincial Hospital, 17 Lujiang Road, Hefei, Anhui, China.', 359.0, 9, 26, 10.0), 
	('Qian Wang', 'lupus_erythematosus', 'Department of Rheumatology, Peking Union Medical College Hospital, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Peking Union Medical College and Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Disease (NCRC-DID), Beijing, China.', 366.4, 5, 21, 9.0), 
	('Yan Zhang', 'lupus_erythematosus', 'Queen Mary Hospital and The University of Hong Kong, Hong Kong, China.', 380.6, 6, 21, 10.0), 
	('Kenneth C Kalunian', 'lupus_erythematosus', 'Division of Rheumatology, University of California at San Diego School of Medicine, La Jolla, CA, USA.', 417.8, 7, 28, 9.0), 
	('David A Roth', 'lupus_erythematosus', 'Research and Development, GSK, Collegeville, Pennsylvania, USA.', 421.0, 7, 38, 7.0), 
	('Raj Tummala', 'lupus_erythematosus', 'BioPharmaceuticals R&D, AstraZeneca US, Gaithersburg, MD, USA.', 444.0, 9, 33, 7.0), 
	('Richard Furie', 'lupus_erythematosus', 'From the Oklahoma Medical Research Foundation, Oklahoma City (J.T.M.); the University of Pennsylvania and the Corporal Michael J. Crescenz VA Medical Center - both in Philadelphia (V.P.W.); Northwell Health, Great Neck, NY (R.F.); Amsterdam University Medical Centers, Amsterdam (R.V.); Charité-Universitätsmedizin, Berlin (T.D.); the Military Medical Academy, Belgrade, Serbia (M.P.); Instituto Centro de Enfermedades Reumáticas, Buenos Aires (J.V.); Independent Public Clinical Hospital Number 4, Medical University of Lublin, Lublin, Poland (M.M.); Centro de Investigación y Tratamiento Reumatológico, Mexico City, Mexico (F.I.-P.); and Bristol Myers Squibb, Princeton, NJ (M.W., S.K., Y.Y., A.G., P.H.S., Z.L., N.A., N.D.).', 447.20000000000005, 15, 71, 9.0), 
	('Josef S Smolen', 'lupus_erythematosus', 'Medical University of Vienna, Vienna, Austria.', 448.20000000000005, 3, 18, 8.0), 
	('Herbert Struemper', 'lupus_erythematosus', 'Quantitative Clinical Development, PAREXEL International on behalf of GlaxoSmithKline, 2520 Meridian Parkway, Suite 200, Durham, NC, 27713, USA. herbert.x.struemper@gsk.com.', 448.8, 5, 19, 9.0), 
	('Daniel J Wallace', 'lupus_erythematosus', 'Division of Rheumatology, Cedars-Sinai Medical Center, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA.', 449.0, 13, 64, 9.0), 
	('Beulah Ji', 'lupus_erythematosus', 'Research and Development, GSK, Brentford, Middlesex, UK.', 455.40000000000003, 6, 26, 6.0), 
	('Xiao-Bo Wang', 'lupus_erythematosus', 'Institute of Aging Research and the Affiliated Hospital, School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.', 461.4, 3, 16, 9.0), 
	('Jing Zhang', 'lupus_erythematosus', 'Queen Mary Hospital and The University of Hong Kong, Hong Kong, China, and Eye and ENT Hospital of Fudan University, Shanghai, China.', 463.4, 5, 19, 10.0), 
	('Caroline Gordon', 'lupus_erythematosus', 'Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.', 470.8, 4, 21, 10.0), 
	('Brad H Rovin', 'lupus_erythematosus', 'Division of Nephrology, The Ohio State University, Columbus, Ohio.', 472.6, 5, 29, 6.0), 
	('Yan-Mei Mao', 'lupus_erythematosus', 'Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, Anhui, China.', 492.6, 9, 23, 7.0), 
	('Bao-Zhu Li', 'lupus_erythematosus', 'Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China.', 494.8, 7, 26, 7.0), 
	('Victoria P Werth', 'lupus_erythematosus', 'From the Oklahoma Medical Research Foundation, Oklahoma City (J.T.M.); the University of Pennsylvania and the Corporal Michael J. Crescenz VA Medical Center - both in Philadelphia (V.P.W.); Northwell Health, Great Neck, NY (R.F.); Amsterdam University Medical Centers, Amsterdam (R.V.); Charité-Universitätsmedizin, Berlin (T.D.); the Military Medical Academy, Belgrade, Serbia (M.P.); Instituto Centro de Enfermedades Reumáticas, Buenos Aires (J.V.); Independent Public Clinical Hospital Number 4, Medical University of Lublin, Lublin, Poland (M.M.); Centro de Investigación y Tratamiento Reumatológico, Mexico City, Mexico (F.I.-P.); and Bristol Myers Squibb, Princeton, NJ (M.W., S.K., Y.Y., A.G., P.H.S., Z.L., N.A., N.D.).', 506.0, 11, 54, 9.0), 
	('Dandan Wang', 'lupus_erythematosus', 'The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China.', 507.2, 5, 28, 10.0), 
	('Alexis Mathian', 'lupus_erythematosus', 'Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupement Hospitalier Pitié-Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France.', 519.6, 3, 21, 11.0), 
	('Michelle A Petri', 'lupus_erythematosus', 'Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.', 519.8, 4, 23, 12.0), 
	('Yoshiya Tanaka', 'lupus_erythematosus', 'The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Kitakyushu, Japan.', 520.0, 19, 83, 9.0), 
	('Guo-Cui Wu', 'lupus_erythematosus', 'School of Nursing, Anhui Medical University, Hefei, 230032, Anhui, China. gcwu82@126.com.', 537.2, 4, 19, 9.0), 
	('Jiuliang Zhao', 'lupus_erythematosus', 'Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.', 545.2, 5, 24, 9.0), 
	('Estibaliz Lazaro', 'lupus_erythematosus', 'CNRS UMR 5164, Immuno ConcEpT, Bordeaux University, 33076 Bordeaux, France; Department of Internal Medicine and Infectious Diseases, Haut Leveque Hospital, University Hospital Centre of Bordeaux, 33604 Pessac, France.', 550.4, 5, 25, 8.0), 
	('Bin Liu', 'lupus_erythematosus', 'Department of Epidemiology, Zhejiang Chinese Medical University School of Public Health, Hangzhou, China.', 552.2, 2, 14, 9.0), 
	('Qian Wu', 'lupus_erythematosus', 'Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, Anhui, China.', 571.0, 6, 24, 6.0), 
	('Eric F Morand', 'lupus_erythematosus', 'School of Clinical Sciences at Monash Health, Monash University, Melbourne, VIC, Australia.', 583.8, 16, 51, 8.0), 
	('Chi Chiu Mok', 'lupus_erythematosus', 'Tuen Mun Hospital, Hong Kong SAR, China.', 584.8, 4, 20, 10.0), 
	('Kenneth Kalunian', 'lupus_erythematosus', 'University of California at San Diego School of Medicine, La Jolla, California.', 587.8, 5, 23, 9.0), 
	('Chan-Na Zhao', 'lupus_erythematosus', 'Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, Anhui, China.', 588.8, 7, 19, 7.0), 
	('Dong-Qing Ye', 'lupus_erythematosus', 'Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China.', 603.0, 13, 49, 9.0), 
	('Min Zhang', 'lupus_erythematosus', NULL, 603.2, 2, 12, 10.0), 
	('Joan T Merrill', 'lupus_erythematosus', 'Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma.', 606.6, 17, 88, 9.0);

INSERT INTO kol_pub_list VALUES 
	('Sang-Cheol Bae', 'Association between the functional ITGAM rs1143679 G/A polymorphism and systemic lupus erythematosus/lupus nephritis or rheumatoid arthritis: an update meta-analysis.'), 
	('Sang-Cheol Bae', 'Meta-analysis of associations between functional HLA-G polymorphisms and susceptibility to systemic lupus erythematosus and rheumatoid arthritis.'), 
	('Sang-Cheol Bae', 'Association of HLA-G polymorphisms with systemic lupus erythematosus and correlation between soluble HLA‑G levels and the disease: a meta-analysis.'), 
	('Sang-Cheol Bae', 'Association between Vitamin D level and/or deficiency, and systemic lupus erythematosus: a meta-analysis.'), 
	('Sang-Cheol Bae', 'Meta-analysis of gene expression profiles of peripheral blood cells in systemic lupus erythematosus.'), 
	('Sang-Cheol Bae', 'Vitamin D receptor FokI, TaqI, and ApaI polymorphisms and susceptibility to systemic lupus erythematosus: an updated meta-analysis.'), 
	('Sang-Cheol Bae', 'Meta-analysis of associations between functional prolactin -1149 G/T polymorphism and susceptibility to rheumatoid arthritis and systemic lupus erythematosus.'), 
	('Sang-Cheol Bae', 'Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population.'), 
	('Sang-Cheol Bae', 'A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.'), 
	('Sang-Cheol Bae', 'Association between the functional PTPN22 G788A (R263Q) polymorphism and susceptibility to autoimmune diseases: A meta-analysis.'), 
	('Sang-Cheol Bae', 'Trial of Anifrolumab in Active Systemic Lupus Erythematosus.'), 
	('Sang-Cheol Bae', 'Association between Functional CYP2D6 Polymorphisms and Susceptibility to Autoimmune Diseases: A Meta-Analysis.'), 
	('Sang-Cheol Bae', 'Association between FCGR3B copy number variations and susceptibility to autoimmune diseases: a meta-analysis.'), 
	('Vibeke Strand', 'Patient-reported outcome measures in systemic lupus erythematosus by a web-based application: A randomized, crossover, agreement study.'), 
	('Vibeke Strand', 'Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment.'), 
	('Vibeke Strand', 'Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials.'), 
	('Vibeke Strand', 'Health-related quality of life in systemic sclerosis compared with other rheumatic diseases: a cross-sectional study.'), 
	('Vibeke Strand', 'Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.'), 
	('Zahir Amoura', 'Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: A meta-analysis of the literature.'), 
	('Zahir Amoura', 'Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis.'), 
	('Zahir Amoura', 'Safety and efficacy of low-dose intravenous arsenic trioxide in systemic lupus erythematosus: an open-label phase IIa trial (Lupsenic).'), 
	('Zahir Amoura', 'Blockade of interferon-γ normalizes interferon-regulated gene expression and serum CXCL10 levels in patients with systemic lupus erythematosus.'), 
	('Zahir Amoura', 'Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature.'), 
	('Fengchun Zhang', 'Association of the IRF5 rs2070197 polymorphism with systemic lupus erythematosus: a meta-analysis.'), 
	('Fengchun Zhang', 'Association between complement 4 copy number variation and systemic lupus erythematosus: a meta-analysis.'), 
	('Fengchun Zhang', 'Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years.'), 
	('Fengchun Zhang', 'Safety of belimumab in adult patients with systemic lupus erythematosus: Results of a large integrated analysis of controlled clinical trial data.'), 
	('Fengchun Zhang', 'A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.'), 
	('Ricard Cervera', 'The impact of antimalarial agents on traditional and non-traditional subclinical atherosclerosis biomarkers in systemic lupus erythematosus: A systematic review and meta-analysis.'), 
	('Ricard Cervera', 'Bone mineral density and vertebral fractures in patients with systemic lupus erythematosus: A systematic review and meta-regression.'), 
	('Ricard Cervera', 'Prevalence of cervical HPV infection in women with systemic lupus erythematosus: A systematic review and meta-analysis.'), 
	('Ricard Cervera', 'Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials.'), 
	('David Isenberg', 'Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).'), 
	('David Isenberg', 'What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials.'), 
	('David Isenberg', 'Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL.'), 
	('David Isenberg', 'Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.'), 
	('David Isenberg', 'Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study.'), 
	('Roger A Levy', 'Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension.'), 
	('Roger A Levy', 'The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis.'), 
	('Roger A Levy', 'Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials.'), 
	('Michelle Petri', 'Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis.'), 
	('Michelle Petri', 'Sub-setting systemic lupus erythematosus by combined molecular phenotypes defines divergent populations in two phase III randomized trials.'), 
	('Michelle Petri', 'Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab.'), 
	('Michelle Petri', 'Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials.'), 
	('Michelle Petri', 'Urine proteomic insights from the belimumab in lupus nephritis trial.'), 
	('Michelle Petri', 'Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).'), 
	('Michelle Petri', 'Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).'), 
	('Michelle Petri', 'Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.'), 
	('Rui-Xue Leng', 'Increased plasma/serum levels of prolactin in systemic lupus erythematosus: a systematic review and meta-analysis.'), 
	('Rui-Xue Leng', 'Association of FCGR2A-R/H131 polymorphism with susceptibility to systemic lupus erythematosus among Asian population: a meta-analysis of 20 studies.'), 
	('Rui-Xue Leng', 'Plasma/Serum Leptin Levels in Patients with Systemic Lupus Erythematosus: A Meta-analysis.'), 
	('Rui-Xue Leng', 'Decreased flow-mediated dilatation in patients with systemic lupus erythematosus: a meta-analysis.'), 
	('Rui-Xue Leng', 'Comparison of plasma/serum levels of procalcitonin between infection and febrile disease flare in patients with systemic lupus erythematosus: a meta-analysis.'), 
	('Rui-Xue Leng', 'Subclinical atherosclerosis in patients with systemic lupus erythematosus: A systemic review and meta-analysis.'), 
	('Rui-Xue Leng', 'Circulating antioxidant levels in systemic lupus erythematosus patients: a systematic review and meta-analysis.'), 
	('Rui-Xue Leng', 'Association between serum/plasma adiponectin levels and immune-mediated diseases: a meta-analysis.'), 
	('Jing Li', 'Association of the IRF5 rs2070197 polymorphism with systemic lupus erythematosus: a meta-analysis.'), 
	('Jing Li', 'Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial.'), 
	('Jing Li', 'An open-label, multiple-dose study to assess the preliminary pharmacokinetics, pharmacodynamics, clinical activity, and safety of human mouse chimeric anti-CD22 monoclonal antibody (SM03) in patients with rheumatoid arthritis.'), 
	('Jing Li', 'Pharmacokinetics, Pharmacodynamics and Preliminary Observations for Clinical Activity and Safety of Multiple Doses of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Chinese Patients with Systemic Lupus Erythematosus.'), 
	('Xiang-Pei Li', 'Thyroid cancer in systemic lupus erythematosus: a meta analysis.'), 
	('Xiang-Pei Li', 'Increased Pulse Wave Velocity in Systemic Lupus Erythematosus: A Meta-Analysis.'), 
	('Xiang-Pei Li', 'Plasma/Serum Leptin Levels in Patients with Systemic Lupus Erythematosus: A Meta-analysis.'), 
	('Xiang-Pei Li', 'Subclinical atherosclerosis in patients with systemic lupus erythematosus: A systemic review and meta-analysis.'), 
	('David D'Cruz', 'Intravenous immunoglobulin in the therapeutic armamentarium of systemic lupus erythematosus: a systematic review and meta-analysis.'), 
	('David D'Cruz', 'Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data.'), 
	('David D'Cruz', 'Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme.'), 
	('David D'Cruz', 'Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.'), 
	('David D'Cruz', 'Tacrolimus use in lupus nephritis: A systematic review and meta-analysis.'), 
	('Yong-Fei Wang', 'Meta-analysis of two Chinese populations identifies an autoimmune disease risk allele in 22q11.21 as associated with systemic lupus erythematosus.'), 
	('Yong-Fei Wang', 'Meta-analysis of genome-wide association study identifies FBN2 as a novel locus associated with systemic lupus erythematosus in Thai population.'), 
	('Yong-Fei Wang', 'Genome-wide association meta-analysis in Chinese and European individuals identifies ten new loci associated with systemic lupus erythematosus.'), 
	('Yong-Fei Wang', 'Meta-analysis of GWAS on both Chinese and European populations identifies GPR173 as a novel X chromosome susceptibility gene for SLE.'), 
	('Yong-Fei Wang', 'Identification of Shared and Asian-Specific Loci for Systemic Lupus Erythematosus and Evidence for Roles of Type III Interferon Signaling and Lysosomal Function in the Disease: A Multi-Ancestral Genome-Wide Association Study.'), 
	('Doruk Erkan', 'Antiphospholipid antibodies and the risk of autoimmune hemolytic anemia in patients with systemic lupus erythematosus: A systematic review and meta-analysis.'), 
	('Doruk Erkan', 'The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository.'), 
	('Doruk Erkan', 'Antiphospholipid antibodies and the risk of thrombocytopenia in patients with systemic lupus erythematosus: A systematic review and meta-analysis.'), 
	('Doruk Erkan', 'A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients.'), 
	('Doruk Erkan', 'Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis.'), 
	('Doruk Erkan', 'Risk of livedo with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis.'), 
	('Mengtao Li', 'Relapse rates and risk factors for unfavorable neurological prognosis of transverse myelitis in systemic lupus erythematosus: A systematic review and meta-analysis.'), 
	('Mengtao Li', 'Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: A PRISMA-compliant systematic review and meta-analysis.'), 
	('Mengtao Li', 'Pharmacokinetics, Pharmacodynamics and Preliminary Observations for Clinical Activity and Safety of Multiple Doses of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Chinese Patients with Systemic Lupus Erythematosus.'), 
	('Mengtao Li', 'Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial.'), 
	('Mengtao Li', 'Efficacy and safety of immunosuppressive agents for adults with lupus nephritis: a systematic review and network meta-analysis.'), 
	('Bin Wang', 'Prevalence of pulmonary hypertension in systemic lupus erythematosus: a meta-analysis.'), 
	('Bin Wang', 'Preeclampsia in systemic lupus erythematosus pregnancy: a systematic review and meta-analysis.'), 
	('Bin Wang', 'Risk of gestational diabetes mellitus in systemic lupus erythematosus pregnancy: a systematic review and meta-analysis.'), 
	('Bin Wang', 'Diagnostic accuracy of miRNAs as potential biomarkers for systemic lupus erythematosus: a meta-analysis.'), 
	('Bin Wang', 'Vaccinations and risk of systemic lupus erythematosus and rheumatoid arthritis: A systematic review and meta-analysis.'), 
	('Bin Wang', 'Elevated Urinary Neutrophil Gelatinase-Associated Lipocalin Is a Biomarker for Lupus Nephritis: A Systematic Review and Meta-Analysis.'), 
	('Bin Wang', 'ANA-positive primary immune thrombocytopaenia: a different clinical entity with increased risk of connective tissue diseases.'), 
	('Xiao-Mei Li', 'Prevalence of pulmonary hypertension in systemic lupus erythematosus: a meta-analysis.'), 
	('Xiao-Mei Li', 'Thyroid cancer in systemic lupus erythematosus: a meta analysis.'), 
	('Xiao-Mei Li', 'Circulating pentraxin-3 levels in patients with systemic lupus erythematosus: a meta-analysis.'), 
	('Xiao-Mei Li', 'Increased Pulse Wave Velocity in Systemic Lupus Erythematosus: A Meta-Analysis.'), 
	('Xiao-Mei Li', 'Serum/plasma homocysteine levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis.'), 
	('Xiao-Mei Li', 'Plasma/Serum Leptin Levels in Patients with Systemic Lupus Erythematosus: A Meta-analysis.'), 
	('Xiao-Mei Li', 'Lack of association between mean platelet volume and disease activity in systemic lupus erythematosus patients: a systematic review and meta-analysis.'), 
	('Xiao-Mei Li', 'Comparison of plasma/serum levels of procalcitonin between infection and febrile disease flare in patients with systemic lupus erythematosus: a meta-analysis.'), 
	('Xiao-Mei Li', 'Subclinical atherosclerosis in patients with systemic lupus erythematosus: A systemic review and meta-analysis.'), 
	('Qian Wang', 'Relapse rates and risk factors for unfavorable neurological prognosis of transverse myelitis in systemic lupus erythematosus: A systematic review and meta-analysis.'), 
	('Qian Wang', 'Relationship between disease activity, organ damage and health-related quality of life in patients with systemic lupus erythematosus: A systemic review and meta-analysis.'), 
	('Qian Wang', 'Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: A PRISMA-compliant systematic review and meta-analysis.'), 
	('Qian Wang', 'Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial.'), 
	('Qian Wang', 'Efficacy and safety of immunosuppressive agents for adults with lupus nephritis: a systematic review and network meta-analysis.'), 
	('Yan Zhang', 'Meta-analysis of two Chinese populations identifies an autoimmune disease risk allele in 22q11.21 as associated with systemic lupus erythematosus.'), 
	('Yan Zhang', 'Gene-based meta-analysis of genome-wide association study data identifies independent single-nucleotide polymorphisms in ANXA6 as being associated with systemic lupus erythematosus in Asian populations.'), 
	('Yan Zhang', 'Genome-wide association meta-analysis in Chinese and European individuals identifies ten new loci associated with systemic lupus erythematosus.'), 
	('Yan Zhang', 'Meta-analysis of GWAS on both Chinese and European populations identifies GPR173 as a novel X chromosome susceptibility gene for SLE.'), 
	('Yan Zhang', 'Meta-analysis of GWAS on two Chinese populations followed by replication identifies novel genetic variants on the X chromosome associated with systemic lupus erythematosus.'), 
	('Yan Zhang', 'Genome-wide search followed by replication reveals genetic interaction of CD80 and ALOX5AP associated with systemic lupus erythematosus in Asian populations.'), 
	('Kenneth C Kalunian', 'A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.'), 
	('Kenneth C Kalunian', 'Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.'), 
	('Kenneth C Kalunian', 'A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).'), 
	('Kenneth C Kalunian', 'Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.'), 
	('Kenneth C Kalunian', 'Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials.'), 
	('Kenneth C Kalunian', 'Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).'), 
	('Kenneth C Kalunian', 'Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.'), 
	('David A Roth', 'Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data.'), 
	('David A Roth', 'An indirect comparison of intravenous and subcutaneous belimumab efficacy in patients with SLE and high disease activity.'), 
	('David A Roth', 'Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials.'), 
	('David A Roth', 'Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme.'), 
	('David A Roth', 'Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE.'), 
	('David A Roth', 'Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.'), 
	('David A Roth', 'A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.'), 
	('Raj Tummala', 'Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study.'), 
	('Raj Tummala', 'Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials.'), 
	('Raj Tummala', 'Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: <i>post-hoc</i> analysis of the Phase IIb MUSE trial of anifrolumab.'), 
	('Raj Tummala', 'Exposure-response analysis for selection of optimal dosage regimen of anifrolumab in patients with systemic lupus erythematosus.'), 
	('Raj Tummala', 'What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials.'), 
	('Raj Tummala', 'Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus.'), 
	('Raj Tummala', 'Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.'), 
	('Raj Tummala', 'Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials.'), 
	('Raj Tummala', 'Causal cascade of direct and indirect effects of anifrolumab on patient-reported outcomes: structural equation modelling of two Phase 3 trials.'), 
	('Richard Furie', 'A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.'), 
	('Richard Furie', 'A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.'), 
	('Richard Furie', 'Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study.'), 
	('Richard Furie', 'Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus.'), 
	('Richard Furie', 'Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.'), 
	('Richard Furie', 'What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials.'), 
	('Richard Furie', 'Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus.'), 
	('Richard Furie', 'Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.'), 
	('Richard Furie', 'Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.'), 
	('Richard Furie', 'Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial.'), 
	('Richard Furie', 'Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.'), 
	('Richard Furie', 'Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial.'), 
	('Richard Furie', 'Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.'), 
	('Richard Furie', 'Trial of Anifrolumab in Active Systemic Lupus Erythematosus.'), 
	('Richard Furie', 'Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study.'), 
	('Josef S Smolen', 'Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis.'), 
	('Josef S Smolen', 'Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways.'), 
	('Josef S Smolen', 'Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.'), 
	('Herbert Struemper', 'Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus.'), 
	('Herbert Struemper', 'Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE.'), 
	('Herbert Struemper', 'Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial.'), 
	('Herbert Struemper', 'Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus.'), 
	('Herbert Struemper', 'Relative Bioavailability of a Single Dose of Belimumab Administered Subcutaneously by Prefilled Syringe or Autoinjector in Healthy Subjects.'), 
	('Daniel J Wallace', 'Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus.'), 
	('Daniel J Wallace', 'Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials.'), 
	('Daniel J Wallace', 'Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE).'), 
	('Daniel J Wallace', 'Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways.'), 
	('Daniel J Wallace', 'Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.'), 
	('Daniel J Wallace', 'Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).'), 
	('Daniel J Wallace', 'Safety of belimumab in adult patients with systemic lupus erythematosus: Results of a large integrated analysis of controlled clinical trial data.'), 
	('Daniel J Wallace', 'Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.'), 
	('Daniel J Wallace', 'Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.'), 
	('Daniel J Wallace', 'Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study.'), 
	('Daniel J Wallace', 'Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study.'), 
	('Daniel J Wallace', 'Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.'), 
	('Daniel J Wallace', 'Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.'), 
	('Beulah Ji', 'A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.'), 
	('Beulah Ji', 'Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data.'), 
	('Beulah Ji', 'The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis.'), 
	('Beulah Ji', 'Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.'), 
	('Beulah Ji', 'Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial.'), 
	('Beulah Ji', 'Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus.'), 
	('Xiao-Bo Wang', 'Ethnicity-stratified analysis of the association between IL-18 polymorphisms and systemic lupus erythematosus in a European population: a meta-analysis.'), 
	('Xiao-Bo Wang', 'Comprehensive Assessment of the Association between FCGRs polymorphisms and the risk of systemic lupus erythematosus: Evidence from a Meta-Analysis.'), 
	('Xiao-Bo Wang', 'Associations between PTPN22 and TLR9 polymorphisms and systemic lupus erythematosus: a comprehensive meta-analysis.'), 
	('Jing Zhang', 'Patients with systemic lupus erythematosus face a high risk of cardiovascular disease: A systematic review and Meta-analysis.'), 
	('Jing Zhang', 'Meta-analysis of two Chinese populations identifies an autoimmune disease risk allele in 22q11.21 as associated with systemic lupus erythematosus.'), 
	('Jing Zhang', 'Gene-based meta-analysis of genome-wide association study data identifies independent single-nucleotide polymorphisms in ANXA6 as being associated with systemic lupus erythematosus in Asian populations.'), 
	('Jing Zhang', 'Meta-analysis of GWAS on two Chinese populations followed by replication identifies novel genetic variants on the X chromosome associated with systemic lupus erythematosus.'), 
	('Jing Zhang', 'Genome-wide search followed by replication reveals genetic interaction of CD80 and ALOX5AP associated with systemic lupus erythematosus in Asian populations.'), 
	('Caroline Gordon', 'Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).'), 
	('Caroline Gordon', 'Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial.'), 
	('Caroline Gordon', 'Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL.'), 
	('Caroline Gordon', 'Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial.'), 
	('Brad H Rovin', 'A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.'), 
	('Brad H Rovin', 'Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study.'), 
	('Brad H Rovin', 'Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.'), 
	('Brad H Rovin', 'B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.'), 
	('Brad H Rovin', 'A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.'), 
	('Yan-Mei Mao', 'Increased circulating CXCL13 levels in systemic lupus erythematosus and rheumatoid arthritis: a meta-analysis.'), 
	('Yan-Mei Mao', 'Circulating pentraxin-3 levels in patients with systemic lupus erythematosus: a meta-analysis.'), 
	('Yan-Mei Mao', 'Increased Pulse Wave Velocity in Systemic Lupus Erythematosus: A Meta-Analysis.'), 
	('Yan-Mei Mao', 'Increased circulating interleukin-8 levels in systemic lupus erythematosus patients: a meta-analysis.'), 
	('Yan-Mei Mao', 'Association between circulating 25-hydroxyvitamin D and systemic lupus erythematosus: A systematic review and meta-analysis.'), 
	('Yan-Mei Mao', 'Circulating Matrix Metalloproteinase-9 Levels in Patients with Systemic Lupus Erythematosus: A Meta-analysis.'), 
	('Yan-Mei Mao', 'Lack of association between mean platelet volume and disease activity in systemic lupus erythematosus patients: a systematic review and meta-analysis.'), 
	('Yan-Mei Mao', 'Diagnostic value of urinary monocyte chemoattractant protein-1 in evaluating the activity of lupus nephritis: a meta-analysis.'), 
	('Yan-Mei Mao', 'Elevated Urinary and Blood Vascular Cell Adhesion Molecule-1 as Potential Biomarkers for Active Systemic Lupus Erythematosus: A Meta-analysis.'), 
	('Bao-Zhu Li', 'A Meta-Analysis of Cardiovascular Events in Systemic Lupus Erythematosus.'), 
	('Bao-Zhu Li', 'Serum/plasma homocysteine levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis.'), 
	('Bao-Zhu Li', 'Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies.'), 
	('Bao-Zhu Li', 'Elevated Blood and Urinary ICAM-1 is a Biomarker for Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.'), 
	('Bao-Zhu Li', 'Comparison of plasma/serum levels of procalcitonin between infection and febrile disease flare in patients with systemic lupus erythematosus: a meta-analysis.'), 
	('Bao-Zhu Li', 'Circulating antioxidant levels in systemic lupus erythematosus patients: a systematic review and meta-analysis.'), 
	('Bao-Zhu Li', 'Essential Trace Element Status in Systemic Lupus Erythematosus: a Meta-analysis Based on Case-Control Studies.'), 
	('Victoria P Werth', 'Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.'), 
	('Victoria P Werth', 'Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.'), 
	('Victoria P Werth', 'Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus.'), 
	('Victoria P Werth', 'Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.'), 
	('Victoria P Werth', 'Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.'), 
	('Victoria P Werth', 'Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.'), 
	('Victoria P Werth', 'Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132.'), 
	('Victoria P Werth', 'Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.'), 
	('Victoria P Werth', 'Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study.'), 
	('Victoria P Werth', 'Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.'), 
	('Victoria P Werth', 'Brief Report: Pharmacodynamics, Safety, and Clinical Efficacy of AMG 811, a Human Anti-Interferon-γ Antibody, in Patients With Discoid Lupus Erythematosus.'), 
	('Dandan Wang', 'Circulating miR-320b Contributes to CD4+ T-Cell Proliferation in Systemic Lupus Erythematosus via MAP3K1.'), 
	('Dandan Wang', 'A CD8 T cell/indoleamine 2,3-dioxygenase axis is required for mesenchymal stem cell suppression of human systemic lupus erythematosus.'), 
	('Dandan Wang', 'Serum IFN-γ Predicts the Therapeutic Effect of Mesenchymal Stem Cells Transplantation in Systemic Lupus Erythematosus Patients.'), 
	('Dandan Wang', 'Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy.'), 
	('Dandan Wang', 'Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study.'), 
	('Alexis Mathian', 'Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: A meta-analysis of the literature.'), 
	('Alexis Mathian', 'Pneumococcal vaccination in patients with systemic lupus erythematosus: A multicenter placebo-controlled randomized double-blind study.'), 
	('Alexis Mathian', 'Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial.'), 
	('Michelle A Petri', 'Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials.'), 
	('Michelle A Petri', 'Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways.'), 
	('Michelle A Petri', 'Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.'), 
	('Michelle A Petri', 'Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.'), 
	('Yoshiya Tanaka', 'A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.'), 
	('Yoshiya Tanaka', 'Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis.'), 
	('Yoshiya Tanaka', 'Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.'), 
	('Yoshiya Tanaka', 'The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysis.'), 
	('Yoshiya Tanaka', 'Up-Regulation of TLR7-Mediated IFN-α Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus.'), 
	('Yoshiya Tanaka', 'Safety, pharmacokinetics, and pharmacodynamics of epratuzumab in Japanese patients with moderate-to-severe systemic lupus erythematosus: Results from a phase 1/2 randomized study.'), 
	('Yoshiya Tanaka', 'Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy.'), 
	('Yoshiya Tanaka', 'Safety and tolerability of sifalimumab, an anti-interferon-α monoclonal antibody, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study.'), 
	('Yoshiya Tanaka', 'Efficacy and safety of tabalumab plus standard of care in Japanese patients with active systemic lupus erythematosus: Subgroup analyses of the ILLUMINATE-1 study.'), 
	('Yoshiya Tanaka', 'Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways.'), 
	('Yoshiya Tanaka', 'Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study.'), 
	('Yoshiya Tanaka', 'Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials.'), 
	('Yoshiya Tanaka', 'Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus.'), 
	('Yoshiya Tanaka', 'Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).'), 
	('Yoshiya Tanaka', 'Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.'), 
	('Yoshiya Tanaka', 'Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial.'), 
	('Yoshiya Tanaka', 'Amiselimod, a sphingosine 1-phosphate receptor-1 modulator, for systemic lupus erythematosus: A multicenter, open-label exploratory study.'), 
	('Yoshiya Tanaka', 'Trial of Anifrolumab in Active Systemic Lupus Erythematosus.'), 
	('Yoshiya Tanaka', 'Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.'), 
	('Guo-Cui Wu', 'Decreased sleep quality in patients with systemic lupus erythematosus: a meta-analysis.'), 
	('Guo-Cui Wu', 'Elevated Circulating Interleukin-17 Levels in Patients with Systemic Lupus Erythematosus: A Meta-analysis.'), 
	('Guo-Cui Wu', 'Subclinical atherosclerosis in patients with systemic lupus erythematosus: A systemic review and meta-analysis.'), 
	('Guo-Cui Wu', 'Association between serum/plasma adiponectin levels and immune-mediated diseases: a meta-analysis.'), 
	('Jiuliang Zhao', 'Efficacy and safety of Janus kinase inhibitors in systemic and cutaneous lupus erythematosus: A systematic review and meta-analysis.'), 
	('Jiuliang Zhao', 'Relapse rates and risk factors for unfavorable neurological prognosis of transverse myelitis in systemic lupus erythematosus: A systematic review and meta-analysis.'), 
	('Jiuliang Zhao', 'Relationship between disease activity, organ damage and health-related quality of life in patients with systemic lupus erythematosus: A systemic review and meta-analysis.'), 
	('Jiuliang Zhao', 'Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension: A PRISMA-compliant systematic review and meta-analysis.'), 
	('Jiuliang Zhao', 'Efficacy and safety of immunosuppressive agents for adults with lupus nephritis: a systematic review and network meta-analysis.'), 
	('Estibaliz Lazaro', 'Assessment of subclinical atherosclerosis in systemic lupus erythematosus: A systematic review and meta-analysis.'), 
	('Estibaliz Lazaro', 'The impact of clopidogrel on plasma-soluble CD40 ligand levels in systemic lupus erythematosus patients: the CLOPUS phase I/II pilot study.'), 
	('Estibaliz Lazaro', 'Hydroxychloroquine for the prevention of fetal growth restriction and prematurity in lupus pregnancy: A systematic review and meta-analysis.'), 
	('Estibaliz Lazaro', 'Interferon α kinoid induces neutralizing anti-interferon α antibodies that decrease the expression of interferon-induced and B cell activation associated transcripts: analysis of extended follow-up data from the interferon α kinoid phase I/II study.'), 
	('Estibaliz Lazaro', 'Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis.'), 
	('Bin Liu', 'Association of the IRF5 rs2070197 polymorphism with systemic lupus erythematosus: a meta-analysis.'), 
	('Bin Liu', 'Genetically determined selenium concentrations and risk for autoimmune diseases.'), 
	('Qian Wu', 'Association of MBL2 gene polymorphisms and systemic lupus erythematosus susceptibility: A meta-analysis.'), 
	('Qian Wu', 'Incidence and prevalence of tuberculosis in systemic lupus erythematosus patients: A systematic review and meta-analysis.'), 
	('Qian Wu', 'Circulating pentraxin-3 levels in patients with systemic lupus erythematosus: a meta-analysis.'), 
	('Qian Wu', 'Increased circulating interleukin-8 levels in systemic lupus erythematosus patients: a meta-analysis.'), 
	('Qian Wu', 'Association between circulating 25-hydroxyvitamin D and systemic lupus erythematosus: A systematic review and meta-analysis.'), 
	('Qian Wu', 'Circulating Matrix Metalloproteinase-9 Levels in Patients with Systemic Lupus Erythematosus: A Meta-analysis.'), 
	('Eric F Morand', 'A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.'), 
	('Eric F Morand', 'Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.'), 
	('Eric F Morand', 'Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus.'), 
	('Eric F Morand', 'Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials.'), 
	('Eric F Morand', 'Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: <i>post-hoc</i> analysis of the Phase IIb MUSE trial of anifrolumab.'), 
	('Eric F Morand', 'Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus.'), 
	('Eric F Morand', 'Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus.'), 
	('Eric F Morand', 'What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials.'), 
	('Eric F Morand', 'Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus.'), 
	('Eric F Morand', 'Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.'), 
	('Eric F Morand', 'Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials.'), 
	('Eric F Morand', 'Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials.'), 
	('Eric F Morand', 'Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).'), 
	('Eric F Morand', 'Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).'), 
	('Eric F Morand', 'Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study.'), 
	('Eric F Morand', 'Trial of Anifrolumab in Active Systemic Lupus Erythematosus.'), 
	('Chi Chiu Mok', 'Safety and immune response of a live-attenuated herpes zoster vaccine in patients with systemic lupus erythematosus: a randomised placebo-controlled trial.'), 
	('Chi Chiu Mok', 'Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population.'), 
	('Chi Chiu Mok', 'Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.'), 
	('Chi Chiu Mok', 'Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis.'), 
	('Kenneth Kalunian', 'Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.'), 
	('Kenneth Kalunian', 'Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial.'), 
	('Kenneth Kalunian', 'Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.'), 
	('Kenneth Kalunian', 'Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.'), 
	('Kenneth Kalunian', 'Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus.'), 
	('Chan-Na Zhao', 'Circulating pentraxin-3 levels in patients with systemic lupus erythematosus: a meta-analysis.'), 
	('Chan-Na Zhao', 'Increased Pulse Wave Velocity in Systemic Lupus Erythematosus: A Meta-Analysis.'), 
	('Chan-Na Zhao', 'Elevated Circulating Interleukin-17 Levels in Patients with Systemic Lupus Erythematosus: A Meta-analysis.'), 
	('Chan-Na Zhao', 'Increased circulating interleukin-8 levels in systemic lupus erythematosus patients: a meta-analysis.'), 
	('Chan-Na Zhao', 'Association between circulating 25-hydroxyvitamin D and systemic lupus erythematosus: A systematic review and meta-analysis.'), 
	('Chan-Na Zhao', 'Circulating Matrix Metalloproteinase-9 Levels in Patients with Systemic Lupus Erythematosus: A Meta-analysis.'), 
	('Chan-Na Zhao', 'Lack of association between mean platelet volume and disease activity in systemic lupus erythematosus patients: a systematic review and meta-analysis.'), 
	('Dong-Qing Ye', 'Meta-analysis of associations between XRCC1 gene polymorphisms and susceptibility to systemic lupus erythematosus and rheumatoid arthritis.'), 
	('Dong-Qing Ye', 'A Meta-Analysis of Cardiovascular Events in Systemic Lupus Erythematosus.'), 
	('Dong-Qing Ye', 'Increased circulating CXCL13 levels in systemic lupus erythematosus and rheumatoid arthritis: a meta-analysis.'), 
	('Dong-Qing Ye', 'Serum/plasma homocysteine levels in patients with systemic lupus erythematosus: a systematic review and meta-analysis.'), 
	('Dong-Qing Ye', 'Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies.'), 
	('Dong-Qing Ye', 'Elevated Blood and Urinary ICAM-1 is a Biomarker for Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.'), 
	('Dong-Qing Ye', 'Serum Adiponectin Levels in Patients With Systemic Lupus Erythematosus: A Meta-analysis.'), 
	('Dong-Qing Ye', 'Diagnostic accuracy of miRNAs as potential biomarkers for systemic lupus erythematosus: a meta-analysis.'), 
	('Dong-Qing Ye', 'The risk factors of avascular necrosis in patients with systemic lupus erythematosus: a meta-analysis.'), 
	('Dong-Qing Ye', 'Subclinical atherosclerosis in patients with systemic lupus erythematosus: A systemic review and meta-analysis.'), 
	('Dong-Qing Ye', 'Elevated Urinary and Blood Vascular Cell Adhesion Molecule-1 as Potential Biomarkers for Active Systemic Lupus Erythematosus: A Meta-analysis.'), 
	('Dong-Qing Ye', 'Circulating antioxidant levels in systemic lupus erythematosus patients: a systematic review and meta-analysis.'), 
	('Dong-Qing Ye', 'Association between serum/plasma adiponectin levels and immune-mediated diseases: a meta-analysis.'), 
	('Min Zhang', 'Thyroid cancer in systemic lupus erythematosus: a meta analysis.'), 
	('Min Zhang', 'The risk factors of avascular necrosis in patients with systemic lupus erythematosus: a meta-analysis.'), 
	('Joan T Merrill', 'Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.'), 
	('Joan T Merrill', 'Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co-Expression Patterns: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.'), 
	('Joan T Merrill', 'Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.'), 
	('Joan T Merrill', 'Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus.'), 
	('Joan T Merrill', 'A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).'), 
	('Joan T Merrill', 'Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.'), 
	('Joan T Merrill', 'Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab.'), 
	('Joan T Merrill', 'Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype.'), 
	('Joan T Merrill', 'Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus.'), 
	('Joan T Merrill', 'Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial.'), 
	('Joan T Merrill', 'Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.'), 
	('Joan T Merrill', 'Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials.'), 
	('Joan T Merrill', 'Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE.'), 
	('Joan T Merrill', 'Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.'), 
	('Joan T Merrill', 'Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.'), 
	('Joan T Merrill', 'Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study.'), 
	('Joan T Merrill', 'Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.');
